Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Nat Rev Drug Discov. 2014 Jun;13(6):419-31. doi: 10.1038/nrd4309. Epub 2014 May 16.

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

Author information

1
AstraZeneca, Innovative Medicines and Early Development, Alderley Park, Macclesfield SK10 4TG, UK.
2
AstraZeneca, Innovative Medicines & Early Development, 141 Portland Street, 10th Floor Cambridge, Massachusetts 02139, USA.

Abstract

Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.

PMID:
24833294
DOI:
10.1038/nrd4309
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center